What it's for (Indications)
- This combined vaccine is indicated for active immunization against measles (rubeola) and rubella (German measles) in susceptible individuals aged 12 months or older.
- Its primary purpose is to prevent these highly contagious viral diseases, which can lead to severe complications, including pneumonia, encephalitis, birth defects (Congenital Rubella Syndrome), and even death.
- Routine immunization with this vaccine is a cornerstone of public health strategies globally, aiming to reduce disease incidence, prevent outbreaks, and ultimately contribute to the elimination of measles and rubella through the establishment of robust herd immunity within communities.
- The vaccine is vital for protecting both vaccinated individuals and vulnerable populations who cannot receive the vaccine.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dose for the measles and rubella vaccine (e.g., Triviraten) is a single 0.5 mL administered subcutaneously, typically into the deltoid region of the upper arm or the anterolateral aspect of the thigh in younger children. The exact immunization schedule may vary based on national guidelines, but the first dose is generally administered to infants at 12 to 15 months of age. A second dose is often recommended, usually between 4 and 6 years of age, or later in adolescence, to ensure robust and long-lasting immunity, especially against measles. Catch-up vaccination schedules are available for older children, adolescents, and adults who may have missed routine immunizations or lack documented immunity. Adherence to the recommended dosing schedule is crucial for optimal protection. |
Safety & Warnings
Common Side Effects
- The measles and rubella vaccine is generally well-tolerated, with most adverse reactions being mild and transient.
- Common side effects include localized reactions at the injection site such as pain, redness, swelling, and tenderness.
- Systemic reactions may include a low-grade fever, malaise, and a transient, mild rash (maculopapular or rubelliform) appearing 5 to 12 days post-vaccination.
- Less common side effects reported are temporary arthralgia or arthritis, particularly in adult women receiving the rubella component, and lymphadenopathy.
- Rare but more serious adverse events can occur, such as febrile seizures (typically benign and not associated with long-term sequelae), transient thrombocytopenia, or severe allergic reactions like anaphylaxis.
- It is important to note that the benefits of vaccination far outweigh the risks of these rare adverse events.
Serious Warnings
- Black Box Warning: **Serious Warnings:** The Measles and Rubella vaccine (e.g., Triviraten) does not carry an FDA-mandated Black Box Warning. However, healthcare providers must be acutely aware of critical contraindications and precautions to ensure patient safety and vaccine efficacy. Foremost, this live attenuated vaccine must *not* be administered to pregnant women or to individuals with severe immunosuppression (e.g., due to HIV/AIDS, congenital immunodeficiency, leukemia, lymphoma, or high-dose corticosteroid therapy). Administration in these populations carries a significant risk of vaccine-associated disease rather than protective immunity. Women of childbearing potential should be advised to avoid pregnancy for at least one month following vaccination. Additionally, individuals with a history of severe allergic reactions (anaphylaxis) to previous doses or vaccine components (neomycin, gelatin) should not receive this vaccine. Careful screening for these conditions is paramount prior to vaccination.
- Healthcare providers should exercise caution when administering the measles and rubella vaccine.
- It should be deferred in individuals with a moderate or severe acute illness, with or without fever, until recovery.
- Individuals with a history of severe allergic reaction (e.
- g.
- , anaphylaxis) to any component of the vaccine, including neomycin or gelatin, or to a previous dose of measles or rubella vaccine, should not receive this vaccine.
- Special consideration is required for individuals with a history of seizures, as fever induced by the vaccine could potentially trigger a febrile seizure.
- Furthermore, vaccination should be postponed for at least three to eleven months, depending on the dose, after receiving antibody-containing blood products (e.
- g.
- , immunoglobulin, blood transfusions), as these can interfere with the vaccine's effectiveness.
How it Works (Mechanism of Action)
The measles and rubella vaccine (e.g., Triviraten) is a live attenuated viral vaccine. It contains weakened, but still viable, strains of the measles virus and the rubella virus, which have been modified to lose their pathogenicity while retaining their immunogenicity. Upon administration, these attenuated viruses replicate in the host, mimicking a natural infection without causing the actual disease. This replication stimulates the immune system to produce both humoral (antibody-mediated) and cell-mediated immune responses. The body generates specific antibodies against the measles and rubella viruses, along with memory B and T cells. This immunological memory ensures that upon subsequent exposure to the wild-type measles or rubella virus, the immune system can rapidly recognize and neutralize the pathogen, thereby providing long-lasting protective immunity and preventing the development of the diseases.
Commercial Brands (Alternatives)
No other brands found for this formula.